skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Ceritinib (Code C115112)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Ceritinib

Definition: An orally available inhibitor of the receptor tyrosine kinase activity of anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, ceritinib binds to and inhibits wild-type ALK kinase, ALK fusion proteins and ALK point mutation variants. Inhibition of ALK leads to both the disruption of ALK-mediated signaling and the inhibition of cell growth in ALK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a variety of tumor cell types.

Display Name: Ceritinib

Label: Ceritinib

NCI Thesaurus Code: C115112 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C3818721  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
2,4-Pyrimidinediamine, 5-chloro-N4-(2-((1-methylethyl)sulfonyl)phenyl)-N2-(5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl)-
LDK 378

External Source Codes: 
CAS Registry Number 1032900-25-6 (see NLM ChemIDplus info)
PDQ Closed Trial Search ID 694589
PDQ Open Trial Search ID 694589 (check for NCI PDQ open clinical trial info)
UMLS CUI C3818721

Other Properties:
     Name Value (qualifiers indented underneath)
code C115112
Contributing_Source CTRP
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom